The therapeutic apheresis market was valued at $1.3 billion in 2023 and is estimated to reach $2.8 billion by 2035, exhibiting a CAGR of 6.7% from 2024 to 2035. Therapeutic apheresis is a medical procedure that involves the removal, treatment, and return of a patient’s blood or specific blood components to manage various diseases. This technique is used to eliminate harmful substances such as toxins, antibodies, or abnormal cells from the bloodstream. Depending on the condition being treated, different types of apheresis can be performed, including plasmapheresis (removal of plasma), leukapheresis (removal of white blood cells), and plateletpheresis (removal of platelets). Therapeutic apheresis is commonly used in the treatment of autoimmune disorders, neurological conditions, and hematological diseases. The procedure is carried out using specialized apheresis machines that separate and process blood components through centrifugation or filtration methods.
The therapeutic apheresis market is driven by increase in prevalence of autoimmune disorders, neurological diseases, and hematological conditions that require targeted blood component removal. Rise in the number of cases of diseases such as myasthenia gravis, and thrombotic thrombocytopenic purpura (TTP) has fueled the demand for therapeutic apheresis procedures. The growing geriatric population, which is more susceptible to chronic and immune-related disorders, further contributes to market expansion.
In addition, technological advancements in apheresis machines, including improved filtration techniques and automated systems, enhance efficiency and safety, driving adoption rate of therapeutic apheresis machines. Development of portable and user-friendly devices facilitates outpatient and home-based apheresis treatments, expanding accessibility. In addition, integration of artificial intelligence and real-time monitoring in apheresis systems supports precision medicine approaches, improving patient outcomes.
However, high procedure costs and the expensive nature of apheresis machines pose significant financial burdens on healthcare facilities and patients, particularly in low- and middle-income regions, thereby hampers the market growth. On the other hand, innovations in apheresis devices, including automation, real-time monitoring, and integration with artificial intelligence, enhance treatment precision and operational efficiency, encouraging wider adoption and providing opportunity for the market growth.
The therapeutic apheresis market is segmented into product type, procedure type, application, end user, and region. By product type, the market is segregated into devices, consumables, and software. By procedure type, the market is categorized into therapeutic plasma exchange (TPE), photopheresis, low density lipid removal, stem cell harvest, and other procedures. By application, the market is categorized into hematology, neurology, oncology, and others. By end user, the market is classified into hospitals, blood centers, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).
Major players that operate in the therapeutic apheresis market are Asahi Kasei Medical Co., Ltd., Terumo Corporation, Fresenius Kabi USA, LLC, Kaneka Corporation, Miltenyi Biotec, B. Braun SE, Baxter International Inc., Becton, Dickson and Company, Medica SPA, and Haemonetics Corporation. Key players have adopted product launch, agreement, collaboration, and others as key developmental strategies to improve the product portfolio of the therapeutic apheresis market. For instance, in August 2023, Fresenius Kabi and Lupagen Inc. announced that the companies have entered into a development and supply agreement for technologies designed to bring the delivery of cell and gene therapies to the bedside. Under the terms of the agreement, Fresenius Kabi will provide their expertise in apheresis collection and automated cell processing equipment which focuses on simplifying and reducing costs for cell and gene therapy through a bedside procedure.
The therapeutic apheresis market is driven by increase in prevalence of autoimmune disorders, neurological diseases, and hematological conditions that require targeted blood component removal. Rise in the number of cases of diseases such as myasthenia gravis, and thrombotic thrombocytopenic purpura (TTP) has fueled the demand for therapeutic apheresis procedures. The growing geriatric population, which is more susceptible to chronic and immune-related disorders, further contributes to market expansion.
In addition, technological advancements in apheresis machines, including improved filtration techniques and automated systems, enhance efficiency and safety, driving adoption rate of therapeutic apheresis machines. Development of portable and user-friendly devices facilitates outpatient and home-based apheresis treatments, expanding accessibility. In addition, integration of artificial intelligence and real-time monitoring in apheresis systems supports precision medicine approaches, improving patient outcomes.
However, high procedure costs and the expensive nature of apheresis machines pose significant financial burdens on healthcare facilities and patients, particularly in low- and middle-income regions, thereby hampers the market growth. On the other hand, innovations in apheresis devices, including automation, real-time monitoring, and integration with artificial intelligence, enhance treatment precision and operational efficiency, encouraging wider adoption and providing opportunity for the market growth.
The therapeutic apheresis market is segmented into product type, procedure type, application, end user, and region. By product type, the market is segregated into devices, consumables, and software. By procedure type, the market is categorized into therapeutic plasma exchange (TPE), photopheresis, low density lipid removal, stem cell harvest, and other procedures. By application, the market is categorized into hematology, neurology, oncology, and others. By end user, the market is classified into hospitals, blood centers, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).
Major players that operate in the therapeutic apheresis market are Asahi Kasei Medical Co., Ltd., Terumo Corporation, Fresenius Kabi USA, LLC, Kaneka Corporation, Miltenyi Biotec, B. Braun SE, Baxter International Inc., Becton, Dickson and Company, Medica SPA, and Haemonetics Corporation. Key players have adopted product launch, agreement, collaboration, and others as key developmental strategies to improve the product portfolio of the therapeutic apheresis market. For instance, in August 2023, Fresenius Kabi and Lupagen Inc. announced that the companies have entered into a development and supply agreement for technologies designed to bring the delivery of cell and gene therapies to the bedside. Under the terms of the agreement, Fresenius Kabi will provide their expertise in apheresis collection and automated cell processing equipment which focuses on simplifying and reducing costs for cell and gene therapy through a bedside procedure.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the therapeutic apheresis market analysis from 2023 to 2035 to identify the prevailing therapeutic apheresis market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the therapeutic apheresis market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global therapeutic apheresis market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- New Product Development/ Product Matrix of Key Players
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Product Type
- Devices
- Consumables
- Software
By Procedure Type
- Therapeutic plasma exchange (TPE)
- Photopheresis
- Low Density Lipid Removal
- Stem Cell Harvest
- Other Procedures
By Application
- Hematology
- Neurology
- Oncology
- Others
By End User
- Hospitals
- Blood Centers
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Terumo Corporation
- Miltenyi Biotech
- B.Braun SE
- Baxter International Inc.
- Haemonetics Corporation
- Becton, Dickinson and Company
- Asahi Kasei Corporation
- Medica SPA
- Kaneka Corporation
- Fresenius SE & Co. KGaA
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: THERAPEUTIC APHERESIS MARKET, BY PRODUCT TYPE
CHAPTER 5: THERAPEUTIC APHERESIS MARKET, BY PROCEDURE TYPE
CHAPTER 6: THERAPEUTIC APHERESIS MARKET, BY APPLICATION
CHAPTER 7: THERAPEUTIC APHERESIS MARKET, BY END USER
CHAPTER 8: THERAPEUTIC APHERESIS MARKET, BY REGION
CHAPTER 9: COMPETITIVE LANDSCAPE
CHAPTER 10: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Terumo Corporation
- Miltenyi Biotech
- B.Braun SE
- Baxter International Inc.
- Haemonetics Corporation
- Becton, Dickinson and Company
- Asahi Kasei Corporation
- Medica SPA
- Kaneka Corporation
- Fresenius SE & Co. KGaA
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
